OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder
January 08, 2020 08:00 ET
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Jan. 08, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia - A Free Webinar from the Brain & Behavior Research Foundation
January 08, 2020 00:00 ET
|
Brain & Behavior Research Foundation
New York, Jan. 08, 2020 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation is hosting a free webinar “Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia”...
Brain & Behavior Research Foundation Awards 2019 Outstanding Achievement Prizes to Nine Leading Psychiatric Researchers
November 06, 2019 10:30 ET
|
Brain & Behavior Research Foundation
New York, Nov. 06, 2019 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation, the world’s largest private funder of mental health research grants, awarded its 2019 Outstanding...
Brain & Behavior Research Foundation Announces Dr. William T. Carpenter, Jr. as the Recipient of the 2019 Pardes Humanitarian Prize in Mental Health
September 26, 2019 10:00 ET
|
Brain & Behavior Research Foundation
New York, Sept. 26, 2019 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced that William T. Carpenter, Jr., M.D., Professor of Psychiatry and Pharmacology at Maryland...
Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
August 05, 2019 07:30 ET
|
Minerva Neurosciences, Inc
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive...
Neuroleptics Market To Reach USD 15.41 Billion By 2026 | Reports And Data
April 15, 2019 12:39 ET
|
Reports And Data
Increase in health awareness is expected to be a prime factor driving the market growth; the rising incidences of mental disorders are also expected to grow the market demand in the future. Market...
Streetwise Reports Examines the Commercial Launch Planned for Schizophrenia Drug
January 24, 2019 07:00 ET
|
Streetwise Reports Llc
SAN FRANCISCO, Jan. 24, 2019 (GLOBE NEWSWIRE) -- DURECT Corp. (DRRX:NASDAQ), a biopharmaceutical company, noted that Indivior Plc announced that it will launch in the U.S. its drug for the treatment...
Study: BrainHQ Shows Promise in Gravely Disabled Patients with Schizophrenia
December 10, 2018 08:00 ET
|
Posit Science
SAN FRANCISCO, Dec. 10, 2018 (GLOBE NEWSWIRE) -- A study, just published in the December print issue of the journal Schizophrenia Research, found that targeted cognitive training using BrainHQ — the...
Nesvik Pharmaceuticals, Inc., Receives Updated U.S. FDA Establishment Registration in Light of New Product Development
August 28, 2018 10:10 ET
|
BioStem Technologies, Inc.
Pompano Beach, FL, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Nesvik Pharmaceuticals, Inc., a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), focused on...
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
August 22, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...